CARVOLIX financials
CARVOLIX
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
969500N30CO4B5N2GN67 Financial statements
(EUR, as reported — unscaled; 112 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €0 | €4.1M |
| Other income | €900.0K | €1.2M |
| Employee benefits expense | €7.7M | €7.2M |
| Raw materials & consumables used | €3.1M | €3.3M |
| Depreciation & amortisation | €2.2M | €2.4M |
| Operating profit (EBIT) | -€23.7M | -€14.6M |
| Profit before tax | -€25.1M | -€14.9M |
| Income tax expense | -€123.0K | -€142.0K |
| Profit for the year | -€25.0M | -€14.7M |
| — attributable to owners | -€25.0M | -€14.7M |
| — attributable to NCI | €0 | €0 |
| Total comprehensive income | -€24.9M | -€14.7M |
| Per share | ||
| Basic EPS | €-0.63 | €-0.41 |
| Diluted EPS | €-0.63 | €-0.41 |
| Free cash flow / share | €-0.29 | €-0.32 |
| Cash flow statement | ||
| Net cash from operating activities | -€11.6M | -€11.3M |
| Income taxes paid | €13.0K | €64.0K |
| Net cash from investing activities | €5.2M | -€480.0K |
| Purchase of PP&E (capex) | €116.0K | €147.0K |
| Purchase of intangibles | €20.0K | €0 |
| Net cash from financing activities | €6.8M | €11.4M |
| Proceeds from borrowings | €2.5M | €0 |
| Repayments of borrowings | €250.0K | €200.0K |
| Lease liability payments | €326.0K | €355.0K |
| Balance sheet | ||
| Total assets | €48.0M | €60.9M |
| Non-current assets | €40.9M | €48.7M |
| Intangible assets & goodwill | €26.8M | €32.2M |
| Current assets | €7.1M | €12.2M |
| Cash & equivalents | €1.7M | €1.2M |
| Total equity | €5.8M | €30.3M |
| — attributable to owners | €5.8M | €30.3M |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €18.8M | €21.1M |
| Long-term borrowings | €11.9M | €14.1M |
| Lease liabilities (non-current) | €728.0K | €508.0K |
| Current liabilities | €23.5M | €9.5M |
| Short-term borrowings | €11.1M | €1.5M |
| Lease liabilities (current) | €371.0K | €281.0K |
| Deferred tax liabilities | €1.1M | €1.4M |
| Derived metrics | ||
| Free cash flow | -€11.7M | -€11.5M |
| Operating margin | — | -355.5% |
| Net margin | — | -357.9% |
| Return on equity | -433.5% | -48.7% |
| Cash conversion ratio | 0.46× | 0.77× |
| Capex coverage | -99.57× | -77.03× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | €122.0K | €66.0K |
| Adjustments For Decrease Increase In Other Operating Receivables | €189.0K | -€1.4M |
| Adjustments For Finance Costs | -€611.0K | €407.0K |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | -€2.0M | €179.0K |
| Adjustments For Income Tax Expense | -€123.0K | -€142.0K |
| Adjustments For Increase Decrease In Other Liabilities | €346.0K | €494.0K |
| Adjustments For Increase Decrease In Trade Account Payable | €1.4M | €1.4M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€10.0K | €0 |
| Adjustments For Sharebased Payments | €528.0K | €778.0K |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €0 | €0 |
| Bank Overdrafts Classified As Cash Equivalents | €1.0K | €6.0K |
| Borrowing Costs Recognised As Expense | -€561.0K | €516.0K |
| Cash Advances and Loans From Related Parties | €600.0K | €0 |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €1.7M | €1.2M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€14.4M | -€11.5M |
| Cash Receipts From Future Contracts Forward Contracts Option Contracts and Swap Contracts Classified As Investing Activities | €0 | €5.0M |
| Cash Repayments of Advances and Loans From Related Parties | €600.0K | €0 |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€24.9M | -€14.7M |
| Current Derivative Financial Assets | €0 | €0 |
| Current Derivative Financial Liabilities | €1.7M | €189.0K |
| Depreciation Expense | €6.6M | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €0 | €0 |
| Equity and Liabilities | €48.0M | €60.9M |
| Gains Losses On Change In Fair Value of Derivatives | -€2.0M | €179.0K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €15.0K | -€11.0K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €0 | €0 |
| Increase Decrease In Cash and Cash Equivalents | €524.0K | -€434.0K |
| Increase Decrease In Working Capital | -€2.8M | -€205.0K |
| Increase Decrease Through Exercise of Options | €29.0K | — |
| Increase Decrease Through Sharebased Payment Transactions | €528.0K | €778.0K |
| Increase Decrease Through Treasury Share Transactions | €207.0K | -€117.0K |
| Intangible Assets Other Than Goodwill | €12.2M | €15.1M |
| Interest Paid Classified As Financing Activities | €94.0K | €104.0K |
| Investment Accounted For Using Equity Method | €0 | €0 |
| Issue of Equity | €0 | €12.9M |
| Issued Capital | €3.9M | €3.9M |
| Noncurrent Derivative Financial Liabilities | €5.0M | €5.0M |
| Noncurrent Provisions For Employee Benefits | €39.0K | €114.0K |
| Number of Shares Outstanding | 39.3M | 39.3M |
| Other Comprehensive Income | €56.0K | €13.0K |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | €0 | €0 |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €56.0K | €13.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €0 | €0 |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €56.0K | €13.0K |
| Other Current Financial Assets | €10.0K | €5.4M |
| Other Current Liabilities | €4.3M | €2.9M |
| Other Current Receivables | €5.3M | €5.5M |
| Other Expense By Nature | €4.9M | €6.9M |
| Other Finance Income Cost | €39.0K | €95.0K |
| Other Inflows Outflows of Cash Classified As Financing Activities | €0 | -€20.0K |
| Other Longterm Provisions | €15.0K | €0 |
| Other Noncurrent Financial Assets | €380.0K | €116.0K |
| Other Revenue | €0 | €4.1M |
| Proceeds From Exercise of Options | €29.0K | €0 |
| Proceeds From Government Grants Classified As Financing Activities | €456.0K | €269.0K |
| Proceeds From Issue of Bonds Notes and Debentures | €5.4M | €0 |
| Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method | €8.9M | €5.2M |
| Property Plant and Equipment Including Rightofuse Assets | €1.5M | €1.2M |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | €3.5M | €10.5M |
| Reserve of Exchange Differences On Translation | €22.0K | €22.0K |
| Retained Earnings | -€95.3M | -€70.9M |
| Share Issue Related Cost | €117.0K | €219.0K |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €0 |
| Share Premium | €97.0M | €97.1M |
| Tax Expense Other Than Income Tax Expense | €75.0K | €65.0K |
| Trade and Other Current Payables To Trade Suppliers | €6.1M | €4.7M |
Methodology
Every line item above is a fact tagged in CARVOLIX's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.